253 related articles for article (PubMed ID: 21787268)
1. Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules.
Caraglia M; Santini D; Bronte G; Rizzo S; Sortino G; Rini GB; Di Fede G; Russo A
Curr Drug Metab; 2011 Dec; 12(10):944-55. PubMed ID: 21787268
[TBL] [Abstract][Full Text] [Related]
2. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
3. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.
Press MF; Lenz HJ
Drugs; 2007; 67(14):2045-75. PubMed ID: 17883287
[TBL] [Abstract][Full Text] [Related]
4. The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics.
Sun GC; Yang X; Yu Y; Zhao DW
Anticancer Agents Med Chem; 2015; 15(7):869-80. PubMed ID: 25783965
[TBL] [Abstract][Full Text] [Related]
5. Functional Inhibition of VEGF and EGFR Suppressors in Cancer Treatment.
Nayarisseri A; Singh SK
Curr Top Med Chem; 2019; 19(3):178-179. PubMed ID: 30950335
[No Abstract] [Full Text] [Related]
6. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
[TBL] [Abstract][Full Text] [Related]
7. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
8. Multi-paratopic VEGF decoy receptor have superior anti-tumor effects through anti-EGFRs and targeted anti-angiogenic activities.
Lee DH; Lee MY; Seo Y; Hong HJ; An HJ; Kang JS; Kim HM
Biomaterials; 2018 Jul; 171():34-45. PubMed ID: 29679794
[TBL] [Abstract][Full Text] [Related]
9. Anti-Angiogenics: Current Situation and Future Perspectives.
Zirlik K; Duyster J
Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab: from bench to bedside.
Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
[TBL] [Abstract][Full Text] [Related]
11. Recent development of molecular-targeted drugs in lung cancer.
Saijo N; Kenmotsu H
Intern Med; 2010; 49(18):1923-34. PubMed ID: 20847494
[TBL] [Abstract][Full Text] [Related]
12. [Recent Developments Towards Molecularly Targeted Therapy of Head and Neck Cancer].
Strieth S; Ernst BP
Laryngorhinootologie; 2017 Mar; 96(3):185-198. PubMed ID: 28420025
[No Abstract] [Full Text] [Related]
13. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
Tabernero J
Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
[TBL] [Abstract][Full Text] [Related]
14. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
Caponigro F; Basile M; de Rosa V; Normanno N
Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
[TBL] [Abstract][Full Text] [Related]
15. Evolving molecular-based targeted therapy for cancer: an exciting field.
Carneiro B; Hsiao K; Khandekar J
Compr Ther; 2005; 31(4):299-305. PubMed ID: 16407611
[TBL] [Abstract][Full Text] [Related]
16. [Molecular target therapy for colonic neoplasms].
Oki E; Ota M; Honbo T; Egashira A; Tokunaga E; Sadanaga N; Morita M; Kakeji Y; Maehara Y
Nihon Naika Gakkai Zasshi; 2007 Feb; 96(2):289-94. PubMed ID: 17370595
[No Abstract] [Full Text] [Related]
17. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer.
Winder T; Lenz HJ
Gastroenterology; 2010 Jun; 138(6):2163-76. PubMed ID: 20420953
[TBL] [Abstract][Full Text] [Related]
18. Molecularly targeted therapy for gastrointestinal cancer.
Wiedmann MW; Caca K
Curr Cancer Drug Targets; 2005 May; 5(3):171-93. PubMed ID: 15892618
[TBL] [Abstract][Full Text] [Related]
19. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy.
Ciardiello F; Troiani T; Bianco R; Orditura M; Morgillo F; Martinelli E; Morelli MP; Cascone T; Tortora G
Ann Oncol; 2006 Jun; 17 Suppl 7():vii109-14. PubMed ID: 16760272
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis inhibitors in the treatment of lung cancer.
Sun S; Schiller JH
Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]